Madelaine Kuiper, MSN, NP, Discusses Rapid Development of HER2-Targeted Therapies
The nurse practitioner from UCLA Health spoke about the expanding treatment options in this setting.
Related Articles
Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma
Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.
Breastfeeding Is Feasible Amid Endocrine Therapy Break in HR+ Breast Cancer
Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
Data from the KEYNOTE-483 trial support the FDA approval of the pembrolizumab-based combination in this pleural mesothelioma population.
Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– Breast Cancer
Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.
Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.
Lenvatinib Improves Efficacy in Real-World Thyroid Cancer Settings
Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast Cancer
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.
Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup
The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.